Press Release
Quantoom Biosciences Prepares for the Implementation of the Ntensify™ Midi System by Afrigen Biologics’ in their GMP Facility, Paving the Way for African-Owned mRNA Vaccine Production
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences Collaborates with Stevanato Group to Elevate mRNA production with Nfinity™ Platform
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences expands its offerings with Nplify, a high-quality linear DNA service for mRNA synthesis
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom expands U.S. Market Reach with Key Appointments
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences installs the first Ntensify™ system for mRNA manufacturing at Afrigen Biologics in Cape Town
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreImmuneWatch, Quantoom Biosciences and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreNew agreement paves way for development of first African-owned COVID-19 vaccine
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreUnivercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
Press Release Univercells acquires Synhelix, entering into synthetic biology and the race to next-generation DNA synthesis January 13, 2022 Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable and automated DNA synthesis technology resulting in one-step generation of long DNA fragments, at…
Read MoreQuantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics
Press Release Quantoom Biosciences granted $13.9 million (€12.4 million), to support the development of its novel MRNA manufacturing platform for vaccines and therapeutics December 20, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large-scale decentralized RNA production economically viable. Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to…
Read More